BioCardia, Inc. (BCDA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09060U6064
BioCardia, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -8.28 m USD |
| EBIT | -8.23 m USD |
| Net income | -8.23 m USD |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
More stocks
- Mobiquity Technologies, Inc. (MOBQ)
- TAP REAL ESTATE TECHNOLOGIES, INC. (RWAX)
- PCS Edventures!, Inc. (PCSV)
- SUNation Energy, Inc. (SUNE)
- HAIN CELESTIAL GROUP INC (HAIN)
- Next Technology Holding Inc. (NXTT)
- Ascent Solar Technologies, Inc. (ASTI)
- BARNWELL INDUSTRIES INC (BRN)
- SPAR Group, Inc. (SGRP)
- Tempus AI, Inc. (TEM)
- M2i Global, Inc. (MTWO)
- FEMASYS INC (FEMY)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.